Practical Updates in Cutaneous Squamous Cell Carcinoma: From Disease Biology to Real-World Management

Dr Gross discusses the key biological and clinical distinctions between cutaneous squamous cell carcinoma and basal cell carcinoma.

Hannah Kenny, MD, and Joseph M. Curry, MD, discuss findings from a phase 2 study of cemiplimab in locally advanced BCC of the head and neck.

A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

From hedgehog pathway mutations to next-generation sequencing, Vernon Sondak, MD, outlines a practical framework for complex BCC and CSCC workup.

Neil D. Gross, MD, FACS, discusses how anti–PD-1 therapy is changing treatment approaches in advanced CSCC.

Neil D. Gross, MD, FACS, discusses the heterogeneous nature of advanced CSCC.

Vernon Sondak, MD, discusses the importance of accurately distinguishing advanced cutaneous squamous cell carcinoma from basal cell carcinoma.